Prognostic significance of telomerase polymorphism in non-small cell lung cancer

Clinical Cancer Research

Volumn 16, Issue 14, 2010, Pages 3706-3712

  Catarino, Raquel ^a,b   Araújo, António ^a   Coelho, Ana ^a   Gomes, Mónica ^a   Nogueira, Augusto ^a   Lopes, Carlos ^a,b   Medeiros, Rui M ^a,c  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; PACLITAXEL; TELOMERASE;

ADULT; ALLELE; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TELOMERE; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TELOMERASE; TREATMENT OUTCOME;

EID: 77954700718     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3030     Document Type: Article

References (43)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003;95:1453-61.
3. Souquet PJ, Geriniere L. The role of chemotherapy in early stage of non-small cell lung cancer. Lung Cancer 2001;34 Suppl 2:S155-8.
4. Paz-Ares L, Ross H, O'Brien M, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 2008;98:1608-13.
5. Rosell R, Felip E, Paz-Ares L. How could pharmacogenomics help improve patient survival? Lung Cancer 2007;57 Suppl 2:S35-41.
6. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci U S A 1995;92:9082-6.
7. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 2005;6:611-22.
8. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
9. Blackburn EH. Telomeres: do the ends justify the means? Cell 1984;37:7-8.
10. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-60.
11. Iwama H, Ohyashiki K, Ohyashiki JH, et al. Telomeric length and telomerase activity vary with age in peripheral blood cells obtained from normal individuals. Hum Genet 1998;102:397-402.
12. Wu X, Amos CI, Zhu Y, et al. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 2003;95:1211-8. (Pubitemid 37069551)
13. Rudolph KL, Millard M, Bosenberg MW, DePinho RA. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 2001;28:155-9. (Pubitemid 32538061)
14. Newbold RF. The significance of telomerase activation and cellular immortalization in human cancer. Mutagenesis 2002;17:539-50.
15. Bieche I, Nogues C, Paradis V, et al. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000;6:452-9. (Pubitemid 30111463)
16. Lee BK, Diebel E, Neukam FW, Wiltfang J, Ries J. Diagnostic and prognostic relevance of expression of human telomerase subunits in oral cancer. Int J Oncol 2001;19:1063-8.
17. Marchetti A, Pellegrini C, Buttitta F, et al. Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation. Lab Invest 2002;82:729-36.
18. Wang L, Soria JC, Kemp BL, Liu DD, Mao L, Khuri FR. hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clin Cancer Res 2002;8:2883-9. (Pubitemid 35025735)
19. Fujita Y, Fujikane T, Fujiuchi S, et al. The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma. Cancer 2003;98:1008-13. (Pubitemid 37022102)
20. Ohali A, Avigad S, Cohen IJ, et al. Association between telomerase activity and outcome in patients with nonmetastatic Ewing family of tumors. J Clin Oncol 2003;21:3836-43. (Pubitemid 46606239)
21. Tchirkov A, Rolhion C, Kemeny JL, et al. Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas. Br J Cancer 2003;88:516-20.
22. Lantuejoul S, Soria JC, Moro-Sibilot D, et al. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer 2004;90:1222-9. (Pubitemid 38496817)
23. Lantuejoul S, Salon C, Soria JC, Brambilla E. Telomerase expression in lung preneoplasia and neoplasia. Int J Cancer 2007;120:1835-41. (Pubitemid 46418357)
24. Blanco D, Vicent S, Fraga MF, et al. Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia 2007;9:840-52.
25. Perera SA, Maser RS, Xia H, et al. Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer. Carcinogenesis 2008;29:747-53.
26. Graakjaer J, Pascoe L, Der-Sarkissian H, et al. The relative lengths of individual telomeres are defined in the zygote and strictly maintained during life. Aging Cell 2004;3:97-102. (Pubitemid 40246672)
27. Londono-Vallejo JA. Telomere length heterogeneity and chromosome instability. Cancer Lett 2004;212:135-44.
28. Matsubara Y, Murata M, Yoshida T, et al. Telomere length of normal leukocytes is affected by a functional polymorphism of hTERT. Biochem Biophys Res Commun 2006;341:128-31. (Pubitemid 43117395)
29. Matsubara Y, Murata M, Watanabe K, et al. Coronary artery disease and a functional polymorphism of hTERT. Biochem Biophys Res Commun 2006;348:669-72. (Pubitemid 44188616)
30. Nordfjall K, Osterman P, Melander O, Nilsson P, Roos G. hTERT (-1327)T/C polymorphism is not associated with age-related telomere attrition in peripheral blood. Biochem Biophys Res Commun 2007;358:215-8. (Pubitemid 46719105)
31. Collins K, Mitchell JR. Telomerase in the human organism. Oncogene 2002;21:564-79.
32. Feldser DM, Hackett JA, Greider CW. Telomere dysfunction and the initiation of genome instability. Nat Rev Cancer 2003;3:623-7.
33. Neumann AA, Reddel RR. Telomere maintenance and cancer - look, no telomerase. Nat Rev Cancer 2002;2:879-84.
34. Mese H, Ueyama Y, Suzuki A, et al. Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line. Chemotherapy 2001;47:136-42.
35. Ducrest AL, Szutorisz H, Lingner J, Nabholz M. Regulation of the human telomerase reverse transcriptase gene. Oncogene 2002;21:541-52.
36. Bisoffi M, Heaphy CM, Griffith JK. Telomeres: prognostic markers for solid tumors. Int J Cancer 2006;119:2255-60.
37. Shirotani Y, Hiyama K, Ishioka S, et al. Alteration in length of telomeric repeats in lung cancer. Lung Cancer 1994;11:29-41.
38. Hirashima T, Komiya T, Nitta T, et al. Prognostic significance of telomeric repeat length alterations in pathological stage I-IIIA non-small cell lung cancer. Anticancer Res 2000;20:2181-7.
39. Frias C, Garcia-Aranda C, De Juan C, et al. Telomere shortening is associated with poor prognosis and telomerase activity correlates with DNA repair impairment in non-small cell lung cancer. Lung Cancer 2008;60:416-25.
40. Fordyce CA, Heaphy CM, Joste NE, Smith AY, Hunt WC, Griffith JK. Association between cancer-free survival and telomere DNA content in prostate tumors. J Urol 2005;173:610-4.
41. Fordyce CA, Heaphy CM, Bisoffi M, et al. Telomere content correlates with stage and prognosis in breast cancer. Breast Cancer Res Treat 2006;99:193-202.
42. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004;23:2919-33.
43. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008;8:167-79.